Photocure ASA

Regulatory Filings • Dec 3, 2015

Photocure: New Hexvix®/Cysview® data to be presented during the 16th Annual SUO in Washington DC

Photocure: New Hexvix®/Cysview® data to be presented during the 16th Annual SUO in Washington DC

Oslo, Norway, December 3, 2015: Photocure (OSE: PHO), a specialty pharmaceutical

company focused on photodynamic technologies in cancer and dermatology, today

announces that new clinical data on Blue Light Cystoscopy with Hexvix/Cysview

will be presented in three separate presentations during the Annual meeting of

Society of Urologic Oncology (SUO) in Washington DC on December 3.

Blue Light Cystoscopy with Hexvix/Cysview is an advancement in detection and

management of non-muscle invasive bladder cancer (NMIBC). The medical benefits

and health economic benefits provided by Hexvix/Cysview have been well

documented and are currently included in several national and international

guidelines on bladder cancer. Hexvix/Cysview has been used in over 300,000

procedures to date, with consistent evidence that it improves detection and

management of bladder cancer compared to White Light Cystoscopy alone.

Kjetil Hestdal, President & CEO comments: "We are pleased with the increased

clinical use of Cysview in the US and the interest by renowned Urology

institutions to evaluate and present new and important clinical data confirming

some of the key medical benefits of the Hexvix/Cysview in management of bladder

cancer patients "

The following clinical presentations on Hexvix/Cysview will be made at the SUO

meeting on December 3:

* BLUE LIGHT CYSTOSCOCPY FOR DIAGNOSIS OF UROTHELIAL BLADDER CANCER RESULTS

FROM PROSPECTIVE REGISTRY from the University of Southern California

Institute of Urology and Norris Comprehensive Cancer Center, Los Angeles,

CA

* BLUE LIGHT CYSTOSCOPY'S EFFECT ON MANAGEMENT OF BLADDER CANCER WHEN COMPARED

TO TRADITIONAL WHITE-LIGHT CYSTOSCOPY from the UT Houston Medical School,

Houston, TX; MD Anderson Cancer Center, Houston, TX

* EXAMINING THE EFFECT THAT PRIOR BLADDER MANIPULATION AND BCG TREATMENT HAVE

ON FALSE POSITIVE RATES OF BLUE LIGHT CYSTOSCOPY BIOPSIES  from UT Houston

Medical School, Houston, TX; MD Anderson Cancer Center, Houston, TX

Access to the full meeting agenda can be found via the following link:

http://bit.ly/1NkAmLq

Bladder cancer affects 577,000 people in the United States, with 74,690 newly

diagnosed patients every year.  Approximately 16,000 patients will die from the

disease in 2015 mainly due to recurrence of the cancer.

*Cysview(®) is tradename in US and Canada, Hexvix(®) in Europe

For further information, please contact:

Photocure

President & CEO Kjetil Hestdal

Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl

Tel: +47 450 55 000, Email: ed@photocure.no

About Photocure ASA

Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical

company and world leader in photodynamic technology. Based on our unique

proprietary Photocure Technology(®) platform, Photocure develops and

commercializes highly selective and effective solutions in disease areas with

high unmet medical need, such as bladder cancer, HPV and precancerous cervical

lesions, colorectal cancer and skin conditions. Our aim is to provide solutions

that can improve health outcomes for patients worldwide. Photocure is listed on

the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at

www.photocure.com.

About Hexvix(®)/Cysview(®)

Hexvix(®)/Cysview(®) (hexaminolevulinate hydro-chloride) is an innovative

breakthrough technology in the diagnosis and management of non-muscle-invasive

bladder cancer. It is designed to selectively target malignant cells in the

bladder and induce fluorescence during a cystoscopic procedure using a blue-

light enabled cystoscope. Using Hexvix(®)/Cysview(®) as an adjunct to standard

white-light cystoscopy enables the urologist to better detect and remove

lesions, leading to a reduced risk of recurrence. Hexvix(®)/Cysview(®) is

approved in Europe, Canada and the USA.

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

[HUG#1971095]